soul trial oral semaglutide cardiovascular outcomes 2025 Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π New in the May 29,
Description
GERD is a condition where stomach acid frequently flows back into the tube connecting your mouth and stomach (esophagus), leading to discomfort and potential damage
Strategic Cycling (The Budget-Friendly Alternative) Strategic cycling involves alternating between active treatment periods (3-6 months on medication) and off periods (3-6 months without)
The 9 mg dose produced an average loss of 64.2 pounds
Learn More Starting at $299/mo Medical Weight Loss without the needle
What is the management of SCAD in acute setting
